ARTL
Artelo Biosciences Inc

10,155
Loading...
Loading...
News
all
press releases
Artelo Biosciences Stock Soars On Strong Preclinical Data In Par With Zoloft For Experimental Depression Drug
The company said that a 28-day treatment regimen with ART12.11 significantly reversed behavioral impairments in male rats exposed to chronic stress, with efficacy on par with the leading antidepressant medication, Sertraline (Zoloft).
Stocktwits·3mo ago
News Placeholder
More News
News Placeholder
Artelo Biosciences Stock Doubles After Positive Results In First Non-Opioid Pain Treatment Trial
The company said that a multiple ascending dose study to evaluate the safety, tolerability, and pharmacokinetics of ART26.12 with repeated dosing over time is expected to commence in the fourth quarter this year.
Stocktwits·3mo ago
News Placeholder
Brokers Offer Predictions for Artelo Biosciences, Inc.'s FY2024 Earnings (NASDAQ:ARTL)
Artelo Biosciences, Inc. (NASDAQ:ARTL - Free Report) - Research analysts at HC Wainwright decreased their FY2024 EPS estimates for shares of Artelo Biosciences in a research note issued on...
Zolmax·1y ago
News Placeholder
Artelo Biosciences, Inc. to Post Q1 2024 Earnings of ($1.05) Per Share, HC Wainwright Forecasts (NASDAQ:ARTL)
Artelo Biosciences, Inc. (NASDAQ:ARTL - Free Report) - Equities researchers at HC Wainwright issued their Q1 2024 earnings per share estimates for shares of Artelo Biosciences in a report released on...
Ticker Report·2y ago
News Placeholder
Artelo Biosciences reports 2023 EPS ($3.14), consensus ($2.56)
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
The Fly·2y ago
News Placeholder
Artelo Biosciences Reports Fiscal 2023 Year-End Financial Results and Provides Business Update
Major achievements in 2023 lay the foundation for key upcoming milestonesSOLANA BEACH, Calif., March 25, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage...
Globe Newswire·2y ago
News Placeholder
Artelo Biosciences, Inc. (NASDAQ:ARTL) Short Interest Up 117.6% in February
Artelo Biosciences, Inc. (NASDAQ:ARTL Get Free Report) was the target of a large growth in short interest in the month of February. As of February 29th, there was short interest totalling...
Ticker Report·2y ago
News Placeholder
Artelo Biosciences Selected as a Finalist in Johnson & Johnson's Innovation Challenge
ART26.12 Preclinical Dermatology Research Presented to the Immuno-dermatology Leadership Team at Johnson & JohnsonSOLANA BEACH, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc...
Globe Newswire·2y ago
News Placeholder
Artelo Biosciences to Present at the Winter Wrap-Up MicroCap Rodeo Conference on February 20th
SOLANA BEACH, CA / ACCESSWIRE / February 15, 2024 / Artelo Biosciences, Inc. (NASDAQ:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Accesswire·2y ago
News Placeholder
Artelo Biosciences Announces Publication of New Peer-Reviewed Pre-Clinical Research Demonstrating ART26.12's Effectiveness in Treating and Preventing Oxaliplatin-Induced Peripheral Neuropathy
SOLANA BEACH, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop...
Globe Newswire·2y ago

Latest ARTL News

View

Advertisement|Remove ads.

Advertisement|Remove ads.